Guggenheim Maintains Buy on GH Research, Raises Price Target to $46
Guggenheim analyst Eddie Hickman maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $40 to $46.

Last updated: 2026-11-19 07:18:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
GH Research PLC (GHRS) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $18.25, with a market capitalization of $1.25B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $12.04 to $31.44. This page covers its latest market performance, valuation, price trends and company information.
$1.25B | |
$18.29 | |
$18.61 | |
$17.51 | |
$18.27 | |
422.39K | |
291.86K | |
-- | |
$31.44 | |
$12.04 | |
-- | |
2026-06-30 |
GH Research PLC (GHRS) last closed at $18.25 as of 2026-11-19 00:31:00, up 0.27% ($0.05) from the previous close of $18.27.
During the latest regular trading session, GHRS traded between $17.51 and $18.61, with a volume of 422.39K shares. The closing price was near the upper end and near the lower end of its 52-week range.
Over the past seven days, GH Research PLC (GHRS) moved from $19.56 to $18.25, representing a decline of 6.69% ($1.31).
The stock traded between $17.51 and $19.85 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 345.66 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 32.0%
GHRS is currently trading at $18.25, placing it 32.0% of the way from its 52-week low of $12.04 to its 52-week high of $31.44. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
| Employees | 73 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to GH Research PLC and GHRS stock.
Guggenheim analyst Eddie Hickman maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $40 to $46.
HC Wainwright & Co. analyst Patrick R. Trucchio maintains GH Research (NASDAQ:GHRS) with a Buy and lowers the price target from $65 to $55.
GH Research shares fell after FDA feedback on Phase 3 TRD design; analysts stayed bullish, citing funding through 2027 and ~$1.2B peak sales.
GH Research (NASDAQ:GHRS) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.32) by 43.75 percent. This is a 21.74 percent increase over losses of $(0.23) per share from the
Eligible investors can buy real shares of GH Research PLC (GHRS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to GHRS, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between GHRS shares and USD.
GHRS Shares to USD
1.00 GHRS shares = 18.251 USD
Calculations are estimates based on the latest available price and are for reference only.